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Abstract: 
With the exponential rise in the number of viable novel drug targets, computational methods are being increasingly applied to 
accelerate the drug discovery process. Virtual High Throughput Screening (vHTS) is one such established methodology to identify 
drug candidates from large collection of compound libraries. Although it complements the expensive and time consuming High 
Throughput Screening (HTS) of compound libraries, vHTS possess inherent challenges. The successful vHTS requires the careful 
implementation of each phase of computational screening experiment right from target preparation to hit identification and lead 
optimization. This article discusses some of the important considerations that are imperative for designing a successful vHTS 
experiment. 
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Background: 
The discovery of novel drug targets has increased exponentially 
in recent years due to advances in genomic and molecular 
biology techniques. Experimental and computational methods 
are effectively applied to accelerate the process of lead 
identification and optimization. The chemical leads are small 
potential drug like molecules which are capable of modulating 
the function of the target proteins that are further optimized to 
act as a therapeutic drug against a targeted disease. Conventional 
experimental methods like High Throughput Screening (HTS) 
continue to be the best method for rapid identification of drug 
leads. HTS identifies lead molecules by performing individual 
biochemical assays with over millions of compounds. However, 
the huge cost and time consumed with this technology has lead 
to the integration of cheaper and effective computational 
methodology namely virtual High Throughput Screening 
(vHTS). vHTS is a computational screening method which is 
widely applied to screen insilico collection of compound 
libraries to check the binding affinity of the target receptor with 
the library compounds [1]. This is achieved by using a scoring 
function which computes the complementarity of the target 
receptor with the compounds. HTS and vHTS are 
complementary methods [2] and vHTS has been shown to 
reduce false positives in HTS [3]. Several vHTS strategies have 
been practiced [4]  and the technique is being continuously 
optimized for better performance.  
 
Methodology: 
Based on the availability of structural data, vHTS is carried out 
using receptor based or ligand based screening methods. 
Receptor based method involves usage of 3D structure of the 
target receptors to search for potential candidate compounds that 
can modulate the target receptor function. Each of the database 
compounds is docked into the receptor binding site and best 
electrostatic fit is predicted. Successful application of receptor 
based method has been reported in many targets [5].  In case 
where structural information of the target is unavailable, ligand 
based method make use of the information provided by known 
inhibitors. Structures similar to the known inhibitors are 
identified from chemical databases by variety of methods, 
including similarity and substructure searching, pharmacophore 
matching and 3D shape matching. Numerous successful 
applications of ligand based methods have also been reported 
[2]. In both the methods, the compounds are ranked using an 
appropriate scoring function based on either complementarity or 
similarity and the top ranking compounds are taken to the next 
step of experimental assays. General workflow of vHTS 
experiment is shown in Figure 1.  
 
Important considerations for vHTS 
Incorporating target flexibility in molecular docking 
Proteins undergo conformational change upon ligand binding 
and due to this rigid protein docking may be inadequate for 
computational drug designing applications [6, 7]. Sampling the 
intrinsic flexibility of the protein binding site remains a great 
challenge in flexible protein docking. Nevertheless this problem 
is being increasingly addressed by several advanced methods 
which aim at accurate representation of protein flexibility and its 
ligand recognition [8]. Most of the attempts to incorporate 
protein flexibility make use of an ensemble of protein structures. 
A crystallographic structure of the same target bound to 
different ligands provides a good starting point to obtain 
ensemble of protein structures. Ensemble of structures derived Bioinformation by Biomedical Informatics Publishing Group                                     open access 
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from NMR studies has been used to incorporate protein 
flexibility in docking studies of HIV-1 protease that has 
demonstrated good docking accuracy [9]. The study has also 
shown that docking against NMR structures provide an efficient 
alternative method for standard docking against individual X-ray 
crystal structures. In the absence of experimental studies, 
conformational ensemble generated by Molecular Dynamics 
(MD) simulations has also been used to dock ligands to flexible 
receptors  [10].  The choice of appropriate docking tool which 
considers reasonable flexibility in protein conformation 
enhances the reliability of prediction of protein binding affinity. 
 
vHTS using Homology models 
In the absence of crystal structures, homology models have 
helped in lead identification process of drug targets like 
falcipain-3  [11] and GPCR [12]. Recently, we have used a 
homology model of a novel drug target of Plasmodium 
falciparum PfHslV [13], an ATP dependant protease and this 
model has helped in the identification of several hit compounds 
(unpublished data). Database of homology models like 
ModWeb [14] and organism specific database like plasmodium 
model database [15] which are being experimentally validated 
can be a good source to obtain the models of target proteins. It 
has been shown that models based on templates with greater 
than 50% sequence identity has yielded 5-fold better enrichment 
than one with less sequence identity [16]. On the other hand, 
small structural errors, such as incorrect assignment of few side 
chain rotamers have been the cause of poor performance. Hence 
successful vHTS using a homology model depends on the 
quality of template crystal structures. 
 
Figure 1: Virtual high throughput screening workflow. 
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Pre - processing chemical databases 
Wide collections of both publicly and commercially available 
compound libraries are screened in the lead identification 
process. The compound collection for screening is usually 
derived from commercial corporate collection or from in silico 
libraries generated by combinatorial methods. Many factors 
contribute to the selection of an appropriate chemical database 
for vHTS. Various kinds of filters are being applied to the 
compound libraries prior to screening in order to: i) increase the 
probability of finding hits with drug like characteristics (ADME 
properties) or lead like characteristics (with physico chemical 
profile of a lead), ii) to ensure the meaningful composition of the 
library to be screened, there by saving computational demand 
while screening.  
 
ADME property filters and toxicity filters 
Most important and widely applied filter is the drug-likeness of 
the compound which represent ADME profile (Adsorption, 
Distribution, Metabolism and Excretion) as determined by 
Lipinski's rule of five, which is a set of rules based on molecular 
weight, lipophilicity and hydrophobicity, H bond donors and H 
bond acceptors [17]. The compounds which are labeled as drug-
like (Figure 2) resembles the existing drug molecules and 
exhibit the following property cut-off values: MW ≤ 500, LogP 
≤ 5, H bond acceptors ≤ 10 and H bond donors ≤ 5. The 
compounds exceeding the cut-off values tend to have solubility 
and permeability problems which would lead to poor oral 
bioavailabity. In addition to the rule of five there are other 
properties which help in distinguishing drug and non drug-like 
compounds. The extensions include polar surface area ≤ 140 Å 
and rotatable bonds ≤ 10. Prediction of toxicity before the 
synthesis of compounds ensures the removal of compounds with 
potential toxic effects. A number of in silico systems for toxicity 
prediction are available, which help in the classification of toxic 
and non-toxic compounds [18]. The above mentioned filters are 
essential to discard compounds without any drug like 
characteristics and undesirable toxic effects before screening. 
Such in silico filters are essential to minimize expensive drug 
failures in the later stage of drug development. 
 
 
Figure 2: Drug-like compounds [21]. 
Meaningful composition of library  
Tautomer enumeration is also an essential step that has been 
shown to enhance the hit rates in the vHTS [19]. Several studies 
have shown that specific tautomeric states of molecules are 
present which interact with the active site residues of the target 
[20]. Tautomers are often recognized as different structures by 
computational applications, leading to different results. Hence 
chemical databases need to be enriched with correct bioactive 
tautomers to ensure reliable results. Removal of compounds 
known to interact with anti targets e.g., hERG (human Ether-a-
go-go Related Gene) channel can be useful [21]. In addition to 
various factors it is important to confirm the compound 
availability or the synthetic feasibility of the compound before 
considering them for vHTS. 
 
Chemical diversity of chemical databases 
Chemical database with wide chemical space and structural 
diversity offers an ideal solution for lead discovery. The basis 
behind such an analysis is that, similar compounds exhibit 
similar physico-chemical and biological properties. A chemical 
database enriched with the representatives of dissimilar 
compounds or diverse chemical structures shall increase the 
probability of finding different leads with similar biological 
activities. It also ensures that database is small but diverse 
enough to be readily managed. Diversity of chemical databases 
is evaluated by examining how much the compounds within the 
library differ in terms of the distribution of their properties. 
Different kinds of diversity quantification are carried out: 
Distance based methods, Cell-partitioning methods and 
clustering methods. At this juncture, it will be useful to mention 
the study on the major chemical databases demonstrating the 
diversity presented in these databases and also the overlapping 
structures in these databases [22]. Such studies provide a view 
of the diverse nature of the database and helps in selecting an 
appropriate chemical database.  
 
Conclusion: 
vHTS is cost-effective and reliable technique that can be applied 
to identify potential leads and avoid undesirable compounds that 
would otherwise result in expensive and time consuming 
experimental methods. However, vHTS often requires careful 
preparation of both target and compound library, use of optimal 
parameters as well as careful analysis of the results. It should be 
noted that experience and knowledge about the target are very 
crucial in identifying true positives in such experiments. We 
have discussed some of the essential considerations in designing 
vHTS experiment focusing the pre-processing of chemical 
databases that are used in vHTS.  
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